P1, N=0, Withdrawn, City of Hope Medical Center | N=18 --> 0 | Trial completion date: Dec 2024 --> Jan 2024 | Recruiting --> Withdrawn | Trial primary completion date: Dec 2024 --> Jan 2024
1 year ago
Enrollment change • Trial completion date • Trial withdrawal • Trial primary completion date • Combination therapy
While studies are ongoing, our results so far suggest potential species-specific differences between LNP targeting properties and underscore the need for testing in the context of human immune system in vitro or in humanized mouse models. We believe that the new LNP2PG formulation will provide vehicle for targeting human hematologic malignancies and solid tumors which rely on the tolerogenic myeloid cells for immune evasion.
over 1 year ago
Immune cell
|
STAT3 (Signal Transducer And Activator Of Transcription 3) • TLR9 (Toll Like Receptor 9) • IFNA1 (Interferon Alpha 1)
P1, N=18, Recruiting, City of Hope Medical Center | Trial completion date: Jan 2024 --> Dec 2024 | Trial primary completion date: Jan 2024 --> Dec 2024
almost 2 years ago
Trial completion date • Trial primary completion date • Combination therapy
|
STAT3 (Signal Transducer And Activator Of Transcription 3)
These studies indicated ~10-fold increase in the potency of our oligonucleotide in local administration resulting in lymphoma growth arrest. While further studies in syngeneic lymphoma models are ongoing, our data suggest that the new LNP-02 formulation of CpG-STAT3siRNA can provide an attractive new therapeutic option for the immunotherapy of B cell lymphoma and potentially certain other malignancies.
over 2 years ago
Preclinical • IO biomarker
|
STAT3 (Signal Transducer And Activator Of Transcription 3) • IFNA1 (Interferon Alpha 1)
P1, N=18, Recruiting, City of Hope Medical Center | Trial completion date: Jul 2023 --> Jan 2024 | Trial primary completion date: Jul 2023 --> Jan 2024
over 2 years ago
Trial completion date • Trial primary completion date • Combination therapy
|
STAT3 (Signal Transducer And Activator Of Transcription 3)